Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation
The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders. This study was performed at the Blida Hospital, where many e...
Uloženo v:
| Vydáno v: | Hypertension research Ročník 34; číslo 10; s. 1116 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.10.2011
|
| Témata: | |
| ISSN: | 1348-4214, 1348-4214 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders. This study was performed at the Blida Hospital, where many early deliveries and pregnancy complications are observed. A total of 164 women were either treated (82) or used as controls (82). Treatment increased the gestation length by 12 days on average, thus triggering an approximate 150-g increase in newborn weight. This consistently improved the outcome for all patients with respect to all parameters investigated. Overall, the relative risk of developing hypertensive disorders of gestation was reduced to 0.07 (confidence interval=0.01-0.51). In our series, we did not observe deleterious consequences for the fetus (teratogenicity and fetotoxicity) or adverse outcomes for the mothers. Despite the limited number of patients analyzed, the present study is one of the largest investigating early aspirin treatment of gestational hypertensive diseases. In addition, the time of aspirin administration is among the earliest yet examined. The data tend to confirm the results obtained from other cohorts on the overall benefit of aspirin treatment for gestational disorders. In the future, molecular or ultrasonographic markers of these diseases could help to screen patients before applying the treatment. |
|---|---|
| AbstractList | The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders. This study was performed at the Blida Hospital, where many early deliveries and pregnancy complications are observed. A total of 164 women were either treated (82) or used as controls (82). Treatment increased the gestation length by 12 days on average, thus triggering an approximate 150-g increase in newborn weight. This consistently improved the outcome for all patients with respect to all parameters investigated. Overall, the relative risk of developing hypertensive disorders of gestation was reduced to 0.07 (confidence interval=0.01-0.51). In our series, we did not observe deleterious consequences for the fetus (teratogenicity and fetotoxicity) or adverse outcomes for the mothers. Despite the limited number of patients analyzed, the present study is one of the largest investigating early aspirin treatment of gestational hypertensive diseases. In addition, the time of aspirin administration is among the earliest yet examined. The data tend to confirm the results obtained from other cohorts on the overall benefit of aspirin treatment for gestational disorders. In the future, molecular or ultrasonographic markers of these diseases could help to screen patients before applying the treatment.The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders. This study was performed at the Blida Hospital, where many early deliveries and pregnancy complications are observed. A total of 164 women were either treated (82) or used as controls (82). Treatment increased the gestation length by 12 days on average, thus triggering an approximate 150-g increase in newborn weight. This consistently improved the outcome for all patients with respect to all parameters investigated. Overall, the relative risk of developing hypertensive disorders of gestation was reduced to 0.07 (confidence interval=0.01-0.51). In our series, we did not observe deleterious consequences for the fetus (teratogenicity and fetotoxicity) or adverse outcomes for the mothers. Despite the limited number of patients analyzed, the present study is one of the largest investigating early aspirin treatment of gestational hypertensive diseases. In addition, the time of aspirin administration is among the earliest yet examined. The data tend to confirm the results obtained from other cohorts on the overall benefit of aspirin treatment for gestational disorders. In the future, molecular or ultrasonographic markers of these diseases could help to screen patients before applying the treatment. The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders. This study was performed at the Blida Hospital, where many early deliveries and pregnancy complications are observed. A total of 164 women were either treated (82) or used as controls (82). Treatment increased the gestation length by 12 days on average, thus triggering an approximate 150-g increase in newborn weight. This consistently improved the outcome for all patients with respect to all parameters investigated. Overall, the relative risk of developing hypertensive disorders of gestation was reduced to 0.07 (confidence interval=0.01-0.51). In our series, we did not observe deleterious consequences for the fetus (teratogenicity and fetotoxicity) or adverse outcomes for the mothers. Despite the limited number of patients analyzed, the present study is one of the largest investigating early aspirin treatment of gestational hypertensive diseases. In addition, the time of aspirin administration is among the earliest yet examined. The data tend to confirm the results obtained from other cohorts on the overall benefit of aspirin treatment for gestational disorders. In the future, molecular or ultrasonographic markers of these diseases could help to screen patients before applying the treatment. |
| Author | Vaiman, Daniel Bakhti, Abdelouahab |
| Author_xml | – sequence: 1 givenname: Abdelouahab surname: Bakhti fullname: Bakhti, Abdelouahab organization: Clinique Hassiba Ben Bouali, Centre Hospitalo-Universitaire de Blida, Blida, Algérie – sequence: 2 givenname: Daniel surname: Vaiman fullname: Vaiman, Daniel |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21881579$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAYhC0Eoh8wsSNvTCl-XSd2RlTxJVWCAebIid8QQ-IE2y3qvyeFIjHdDc_dSTcjx653SMgFsAWwpbpu_IIzgAUAHJEpLIVKBAdx_M9PyCyEd8a4SnM4JRMOSkEq8ykZnj1u0UXbO9rX9M3rrTW2ouhMHxtsrW5psxvQR3RhD5U7qsNgvXU0etSxG8NUm846GyJ6NLT2fUfHLFWxoV-IHz_FGKLer5yRk1q3Ac8POievd7cvq4dk_XT_uLpZJ5VQEBPATJZLgTpD4GkumS5R1lwalSohysxokdUVQ5FLWXGDFVZGphJ0KnVWViWfk6vf3sH3n5txvehsqLBttcN-EwqVZylXLMtH8vJAbsoOTTF422m_K_5O4t-97m0m |
| CitedBy_id | crossref_primary_10_1038_hr_2016_107 crossref_primary_10_1186_s40001_023_01024_7 crossref_primary_10_1007_s00404_024_07373_w crossref_primary_10_1016_j_preghy_2022_10_009 crossref_primary_10_1016_j_drudis_2020_05_011 crossref_primary_10_1017_S0965539512000101 crossref_primary_10_1097_AOG_0000000000001848 crossref_primary_10_1097_HCO_0b013e3283558773 crossref_primary_10_1016_j_ajog_2016_10_016 crossref_primary_10_1016_j_ancard_2012_04_006 crossref_primary_10_1038_hr_2011_121 crossref_primary_10_1186_s12884_024_06413_2 crossref_primary_10_1007_s00404_021_06349_4 crossref_primary_10_1007_s11906_016_0664_3 crossref_primary_10_1186_s13643_022_01978_5 crossref_primary_10_1016_j_ejogrb_2021_05_017 crossref_primary_10_1161_HYPERTENSIONAHA_111_202994 crossref_primary_10_3389_fcvm_2022_936560 crossref_primary_10_1016_j_ajogmf_2024_101595 crossref_primary_10_1016_j_ajog_2019_08_047 crossref_primary_10_3390_reprodmed6020008 crossref_primary_10_3390_ijms20184370 crossref_primary_10_1016_j_gofs_2017_06_016 crossref_primary_10_1016_j_cll_2016_01_013 crossref_primary_10_1007_s11906_020_01039_z crossref_primary_10_1016_j_ajog_2016_09_076 crossref_primary_10_1097_HJH_0000000000001695 crossref_primary_10_1002_ijgo_14910 crossref_primary_10_1002_uog_14889 crossref_primary_10_1002_rfc2_97 crossref_primary_10_1002_pd_4403 crossref_primary_10_3892_etm_2018_5972 crossref_primary_10_1002_uog_12421 crossref_primary_10_1038_s41420_019_0170_x crossref_primary_10_1002_uog_20859 crossref_primary_10_1016_j_ajogmf_2023_100878 crossref_primary_10_1016_j_ajog_2017_11_561 crossref_primary_10_1016_j_ajog_2023_04_031 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1038/hr.2011.111 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1348-4214 |
| ExternalDocumentID | 21881579 |
| Genre | Journal Article |
| GroupedDBID | --- -Q- .55 0R~ 29I 2WC 39C 4.4 406 53G 5GY 70F 7X7 88E 8FI 8FJ AACDK AANZL AASML AATNV ABAKF ABAWZ ABDBE ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACRQY ACZOJ ADBBV AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AFBBN AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AXYYD AYFIA BAWUL BENPR BKKNO BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DIK DNIVK DPUIP DU5 E3Z EBLON EBS ECM EE. EIF EIOEI EJD EMB EMOBN F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GX1 HMCUK HZ~ IWAJR JSF JSH JSO JZLTJ KQ8 LGEZI LOTEE M1P NADUK NPM NQJWS NXXTH O9- OK1 P2P PHGZT PQQKQ PROAC PSQYO RJT RNT RNTTT ROL RZJ SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TKC TR2 TSG UKHRP W2D X7M XSB 7X8 ABBRH ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR SOJ |
| ID | FETCH-LOGICAL-c481t-1e67b34ea6e125970abe7f27d85844b6da46fc0e4977c2dececd7571a57a6bcb2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 40 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000295836200013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1348-4214 |
| IngestDate | Sun Sep 28 02:10:49 EDT 2025 Thu Apr 03 07:07:33 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c481t-1e67b34ea6e125970abe7f27d85844b6da46fc0e4977c2dececd7571a57a6bcb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.nature.com/articles/hr2011111.pdf |
| PMID | 21881579 |
| PQID | 896528069 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_896528069 pubmed_primary_21881579 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-10-01 |
| PublicationDateYYYYMMDD | 2011-10-01 |
| PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Hypertension research |
| PublicationTitleAlternate | Hypertens Res |
| PublicationYear | 2011 |
| References | 21881575 - Hypertens Res. 2011 Oct;34(10):1073-4 Hypertens Res. 2012 Feb;35(2):244 |
| References_xml | – reference: - Hypertens Res. 2012 Feb;35(2):244 – reference: 21881575 - Hypertens Res. 2011 Oct;34(10):1073-4 |
| SSID | ssj0028591 |
| Score | 2.1670063 |
| Snippet | The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1116 |
| SubjectTerms | Adult Aspirin - administration & dosage Birth Weight - drug effects Dose-Response Relationship, Drug Endothelium, Vascular - drug effects Female Fetal Diseases - epidemiology Fetal Diseases - prevention & control Follow-Up Studies Humans Hypertension, Pregnancy-Induced - drug therapy Hypertension, Pregnancy-Induced - epidemiology Hypertension, Pregnancy-Induced - prevention & control Infant, Newborn Platelet Aggregation Inhibitors - administration & dosage Pre-Eclampsia - drug therapy Pre-Eclampsia - epidemiology Pregnancy Pregnancy Trimester, First Premature Birth - epidemiology Premature Birth - prevention & control Risk Factors Risk Reduction Behavior Treatment Outcome Young Adult |
| Title | Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21881579 https://www.proquest.com/docview/896528069 |
| Volume | 34 |
| WOSCitedRecordID | wos000295836200013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1Fe8sAaNU4dPyaEEBUDrToA6hbZzlmtQElpCoh_j-0k3RADSxbHkWVf7O_83X2H0DVQqRkAi6wkEFFgLFLK0shLjVARG0VCfsXLIx-NxGQix01sTtWEVbZ7Ytio89L4O_KekCz1LKC8mb9HvmiUJ1ebChrrqNN3SMYbNZ-sSIQgzRb8LX9nlhDapOfFfdGbLmr1TkLI79AyHDGD3X8Obg_tNNgS39bGsI_WoDhAW8OGPT9E81avqSxwabGvPDRzbRiK3OdhvTlTxFPnly5CVLt7SX9j5Zn4WYFXAelYNXK7vsgn9tkp2PXFYjnFXwCv4cNQ1QT_EXoe3D_dPURNxYXIUEGWEQHGdZ-CYuCAj-Sx0sBtwnPhcArVLFeUWRO7BebcJDkYMDlPOVEpV0wbnRyjjaIs4BRh5tq0SAhIBRTiXEnv_bBc6lRZyW0X4XYqM2fRnqZQBZQfVbaazC46qZcjm9fKG5nDI4KkXJ793fkcbSdtuB65QB3r_ma4RJvmczmrFlfBUtxzNB7-AJA4zF4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevention+of+gravidic+endothelial+hypertension+by+aspirin+treatment+administered+from+the+8th+week+of+gestation&rft.jtitle=Hypertension+research&rft.au=Bakhti%2C+Abdelouahab&rft.au=Vaiman%2C+Daniel&rft.date=2011-10-01&rft.issn=1348-4214&rft.eissn=1348-4214&rft.volume=34&rft.issue=10&rft.spage=1116&rft_id=info:doi/10.1038%2Fhr.2011.111&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1348-4214&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1348-4214&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1348-4214&client=summon |